Becton, Dickinson and Company (NYSE:BDX) to Post Q3 2024 Earnings of $3.30 Per Share, Zacks Research Forecasts

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research dropped their Q3 2024 earnings estimates for Becton, Dickinson and Company in a report issued on Thursday, May 23rd. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will earn $3.30 per share for the quarter, down from their prior estimate of $3.43. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $13.04 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2024 earnings at $3.86 EPS, FY2024 earnings at $13.01 EPS, Q1 2025 earnings at $2.87 EPS, Q2 2025 earnings at $3.44 EPS and Q1 2026 earnings at $3.21 EPS.

Separately, Barclays increased their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $281.40.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $230.35 on Friday. The firm has a fifty day moving average price of $237.82 and a 200-day moving average price of $238.54. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The stock has a market cap of $66.57 billion, a PE ratio of 50.74, a price-to-earnings-growth ratio of 2.05 and a beta of 0.45. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.86 earnings per share.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.65%. Becton, Dickinson and Company’s dividend payout ratio is 83.70%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the transaction, the executive vice president now owns 14,608 shares of the company’s stock, valued at approximately $3,457,713.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,597 shares of company stock worth $2,028,786. 0.31% of the stock is owned by insiders.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors have recently bought and sold shares of BDX. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $27,000. OLD Point Trust & Financial Services N A purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $29,000. DiNuzzo Private Wealth Inc. purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $30,000. Scarborough Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $32,000. Finally, Fortitude Family Office LLC purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $35,000. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.